FUNCTION / METABOLISM / EVIDENCE
Metabolic & Weight research peptides. Outcomes beyond scale weight.
Semaglutide, tesamorelin, and MOTS-c act through different systems. This digest tracks what changes, what may function better, and where the evidence stops.
Semaglutide
A GLP-1 receptor agonist with large human trials for weight, cardiovascular, and kidney outcomes. Appetite and scale weight are only part of its evidence base.
Read the file »
Tesamorelin
The lead file. A GHRH analogue studied for visceral fat, liver fat, lean mass, and the consequences of stimulating the GH–IGF-1 axis.
Read the lead file »
MOTS-c
A mitochondrial-derived peptide tied to muscle glucose handling, stress signaling, and physical performance in preclinical work. Human efficacy remains untested.
Read the file »Start with function
Scale weight is one measure. It is not the whole metabolic record. This digest reads three peptide research programs through function: where fat is stored, how much lean tissue remains, whether mobility changes, how energy is handled, and whether clinical events move with the intervention.
The three compounds are not versions of one idea. Semaglutide acts on the GLP-1 receptor, a target involved in appetite and glucose control. Tesamorelin stimulates the body’s growth-hormone pathway and has direct trial data on visceral fat, liver fat, and lean mass. MOTS-c is made from a mitochondrial gene and is being studied as a signal between cellular energy systems and the nucleus.
Evidence strength differs sharply. Semaglutide and tesamorelin have human randomized trials, though in different populations and for different outcomes. MOTS-c findings are mainly from cells and animals. That distinction governs every page here.
Three systems. Three outcome sets.
Semaglutide: intake and clinical risk. Semaglutide is a long-acting GLP-1 receptor agonist. Its most visible result is lower body weight. The broader file also includes cardiovascular and kidney endpoints. In SELECT, semaglutide reduced major adverse cardiovascular events among adults with established cardiovascular disease and overweight or obesity but without diabetes [3]. In FLOW, it reduced a composite of major kidney outcomes among people with type 2 diabetes and chronic kidney disease [2]. Those are clinical-event outcomes, not proxy measures.
Tesamorelin: distribution and composition. Tesamorelin is the lead because its central question fits this desk exactly: what changes when body composition is examined beyond total weight? A pooled analysis found lower visceral and trunk fat, lower hepatic fat, and higher lean body mass in randomized trials involving HIV-associated lipodystrophy [6]. The population boundary matters. These findings do not establish the same effects in general obesity.
MOTS-c: energy signaling and movement. MOTS-c research asks whether a peptide encoded by mitochondria can coordinate cellular stress, glucose handling, and muscle function. A mouse study linked it to skeletal-muscle glucose uptake and protection from atrophy through casein kinase 2 signaling [13]. Another mouse study reported gains in running capacity, grip, and gait [16]. These are preclinical findings. They are a reason for study, not proof of human benefit.
What counts as a functional metabolic outcome
A functional outcome describes more than a smaller number on a scale. It can be a direct measure of movement, a body-composition measure tied to function, a tissue-specific change, or a clinical event that matters to health.
This frame puts several questions in view. Does fat fall from the visceral compartment around internal organs? Does liver fat change? Is lean mass preserved, gained, or lost? Does muscle take up glucose differently? Does gait, grip, or endurance improve in a model that can measure it? Do kidney or cardiovascular events change in a defined clinical population?
The frame also exposes gaps. A weight-loss result does not by itself describe muscle quality. A biomarker association does not show that administering a peptide changes an outcome. A mouse performance test cannot be translated into a human claim. A result in HIV-associated lipodystrophy does not automatically generalize to routine weight management. The comparison page keeps these boundaries visible and puts each compound against the outcome it actually measured.
What are research peptides?
Peptides are short chains of amino acids. Some work as hormones or signals. Researchers can study natural peptides, modified analogues, and synthetic compounds designed to last longer or engage a specific receptor.
The label research peptide says little about evidence maturity. Semaglutide is an approved prescription medicine in defined formulations and indications. Tesamorelin is also an approved prescription medicine, but for a narrow indication involving excess abdominal fat in adults with HIV-associated lipodystrophy [7]. MOTS-c has no approved human use and no completed human efficacy program in this source set. Grouping them on one hub is useful only if these regulatory and evidentiary differences stay intact.
This site treats published findings as bounded records. It separates human interventions from observational data, cells, and animal models. It labels community reports as anecdotes when they appear. It gives no human dosing and makes no treatment recommendation. The aim is simple: make the literature easier to inspect without making it sound more settled than it is.